ResearcherThe University of Kansas Cancer CenterNo recent work listed

Giridharan Periyasamy

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-2506-7602; OpenAlex author ID A5069194237. Sources: OpenAlex.

Their work

Papers: 2 (first author 1, last author 1)
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 4

Papers, trials and grants by year

2011: 1 paper · 2012: 1 paper

Papers 2

CDK-4 inhibitor P276 sensitizes pancreatic cancer cells to gemcitabine-induced apoptosis. First author DOI 10.1158/1535-7163.mct-12-0102 ↗
Ets-1 expression and gemcitabine chemoresistance in pancreatic cancer cells. Last author DOI 10.2478/s11658-010-0043-z ↗

Closest collaborators

The 4 strongest of 4 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Amit Khanna · 1 shared paper, 2011 · strength 0.04
- Paper Ets-1 expression and gemcitabine chemoresistance in pancreatic cancer cells. DOI 10.2478/s11658-010-0043-z ↗
Sivapriya Ponnurangam · 1 shared paper, 2012 · strength 0.03
- Paper CDK-4 inhibitor P276 sensitizes pancreatic cancer cells to gemcitabine-induced apoptosis. DOI 10.1158/1535-7163.mct-12-0102 ↗
Dharmalingam Subramaniam · 1 shared paper, 2012 · strength 0.03
- Paper CDK-4 inhibitor P276 sensitizes pancreatic cancer cells to gemcitabine-induced apoptosis. DOI 10.1158/1535-7163.mct-12-0102 ↗
Shrikant Anant · 1 shared paper, 2012 · strength 0.03
- Paper CDK-4 inhibitor P276 sensitizes pancreatic cancer cells to gemcitabine-induced apoptosis. DOI 10.1158/1535-7163.mct-12-0102 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.